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With major advances in experimental techniques to track antigen-specific immune
responses many basic questions on the kinetics of virus-specific immunity in humans
remain unanswered. To gain insights into kinetics of T and B cell responses in human
volunteers we combined mathematical models and experimental data from recent studies
employing vaccines against yellow fever and smallpox. Yellow fever virus-specific CD8 T
cell population expanded slowly with the average doubling time of 2 days peaking 2.5
weeks post immunization. Interestingly, we found that the peak of the yellow fever-specific
CD8 T cell response was determined by the rate of T cell proliferation and not by the
precursor frequency of antigen-specific cells as has been suggested in several studies in
mice. We also found that while the frequency of virus-specific T cells increased slowly,
the slow increase could still accurately explain clearance of yellow fever virus in the
blood. Our additional mathematical model described well the kinetics of virus-specific
antibody-secreting cell and antibody response to vaccinia virus in vaccinated individuals
suggesting that most of antibodies in 3 months post immunization were derived from the
population of circulating antibody-secreting cells. Taken together, our analysis provided
novel insights into mechanisms by which live vaccines induce immunity to viral infections
and highlighted challenges of applying methods of mathematical modeling to the current,
state-of-the-art yet limited immunological data.
Keywords: vaccines, T cell responses, mathematical modeling, yellow fever vaccine, smallpox vaccine, antibody-
producing cells
1. INTRODUCTION
With the invention of novel experimental techniques to track
antigen-specific cellular and humoral responses we have gained
insights into magnitude and diversity of T cell responses in mice
and humans (Altman et al., 1996; Murali-Krishna et al., 1998; Su
and Davis, 2013). Imaging and tetramer enrichment techniques
have been used to evaluate antigen-specific T cell responses in
the whole mouse (Reinhardt et al., 2001; Moon et al., 2007; Obar
et al., 2008; Gruta et al., 2010). These and other studies suggest
that in major secondary lymphoid organs of mice there is only
10–1500 of naive CD8 or CD4 T cells specific to a given epitope
that is translated into precursor frequency of 1–100 per 106 of
naive T cells (reviewed in Jenkins and Moon, 2012). A similar
precursor frequency of naive T cells was found in humans (Alanio
et al., 2010; Jenkins and Moon, 2012).
Studies in mice have found a very consistent picture of the T
cell immune response to an antigen (Antia et al., 2005; Obar et al.,
2008). Antigen-specific T cells start dividing after 1–2 days follow-
ing exposure to an antigen, and the number of T cells increases
exponentially in the next 4–5 days. After the peak the number of T
Abbreviations: YFV, yellow fever virus; VV, vaccinia virus; LCMV, lympho-
cytic choriomeningitis virus; SIV, simian immunodeficiency virus; NLME, non-
linear mixed effects; NLS, non-linear least squares; RU, relative units; ASCs,
antibody-secreting cells.
cells declines exponentially, and within the next 2–3 weeks a rela-
tively constant number of memory T cells is established. Memory
CD8 T cells are maintained at a constant level for life of the ani-
mal while memory CD4 T cells are slowly lost (Homann et al.,
2001).
Because there is a strong correlation between the number
of memory T cells generated following an infection and effec-
tor T cells present at the peak of the immune response, factors
contributing to the magnitude of the effector T cell response
have been a subject of debate. Earlier studies proposed that
in mice the magnitude of the T cell response is mainly deter-
mined by the number of naive epitope-specific T cells or the
precursor frequency (Moon et al., 2007; Kotturi et al., 2008;
Obar et al., 2008). Another study, however, by tracking T cell
response to multiple epitopes of the same virus (influenza)
found that precursor frequency is a poor predictor of the peak
immune response (La Gruta et al., 2010). It remains unclear
which factors determine magnitude of the T cell response to
infection or vaccination in humans (Chen et al., 2000). In con-
trast with studies in mice (De Boer et al., 2001, 2003; Althaus
et al., 2007) the temporal kinetics of the T cell responses to
viruses in humans have not been analyzed using mathematical
models.
Although antibody responses to haptens have been used to
form the basis of our understanding of humoral immunity, many
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quantitative details of B cell responses still remain incompletely
understood. Generation of virus-specific antibodies, plasma cells,
and memory B cells in spleen and bone marrow of mice has
been nicely tracked in a now classical study (Slifka et al., 1998).
More recent work also identified rates of B cell division and
death during germinal center reaction (Anderson et al., 2009).
Yet, quantitative properties of humoral responses to pathogens in
humans such as the rate of B cell proliferation, the rate of antibody
production and its change over the course of infection remain
largely unknown.
In humans, following an immune response to a pathogen caus-
ing an acute infection represents a challenge because it is often
hard to know when a person was infected and many acute viral
infections tend to be of a relatively short duration (Carrat et al.,
2008). In contrast, there is a better understanding of the kinet-
ics of cellular and antibody responses to several chronic viruses of
humans such as HIV and HCV (McMichael et al., 2010; Perreau
et al., 2013; Park and Rehermann, 2014). Vaccination with live
viruses represents a convenient way to study human immune
responses. In our analysis we focus on the data coming from
two recent trials with two highly efficacious vaccines: yellow fever
virus (YFV) vaccine 17D (YF-17D) and vaccinia virus (VV) vac-
cine (Miller et al., 2008; Ahmed and Akondy, 2011). To date, over
540 million doses of YF-17D have been administered, and this
vaccine remains one of the safest and effective vaccines in humans
(Cottin et al., 2013; Gotuzzo et al., 2013). Vaccinia virus has been
used as a vaccine against smallpox. The vaccine is highly efficient
and induces life-long humoral immunity and long-term cellular
immunity (Hammarlund et al., 2003; Amanna et al., 2007, 2008).
We use experimental data on the kinetics of virus-specific CD8
T cell, antibody-secreting cell, and antibody responses to these
viruses to obtain insights into mechanisms leading to the gener-
ation of efficient immune memory (Miller et al., 2008; Akondy
et al., 2009).
2. MATERIALS AND METHODS
2.1. EXPERIMENTAL DATA
The data were generated following vaccination of healthy vol-
unteers of age 21-32 with the YF-17D or smallpox vaccines and
were described in detail in previous publications (Miller et al.,
2008; Akondy et al., 2009). In short, volunteers were vaccinated
with 0.5ml of the YF-17D vaccine. Virus-specific CD8 T cells
were identified using tetramer staining (HLA-A2 restricted T
cells recognizing NS4B epitope of YFV (Akondy et al., 2009, see
Figure 3B) or VVCLT of VV (Miller et al., 2008, see Figure 5C)
on days 3, 11, 14, 30, and 90. YFV virus titers were determined as
described previously (Akondy et al., 2009) and here the average
among all patients was used (Akondy et al., 2009, see Figure 3B).
VV-specific antibody titers and frequency of antibody-secreting
cells were measured on days 0, 7, 14, 21, 28, and 84 after Dryvax
immunization. VV-virus specific antibodies were determined as
previously described (Newman et al., 2003). Antibody-secreting
cells were identified by flow cytometry as CD27hi CD38hi CD3−
CD20lo/− PBMCs as described previously (Wrammert et al.,
2008).
2.2. MATHEMATICAL MODEL FOR CD8+ T CELL KINETICS
A simple mathematical model has been previously used to
describe kinetics of virus-specific CD8 T cell response in acute
and chronic LCMV infection (De Boer et al., 2001, 2003; Althaus
et al., 2007). We adopted this model to quantify T cell response
in humans (Riou et al., 2012, see Figure 1A). In the model,
virus-specific immune response expands exponentially from E0
precursors at a rate ρ and reaches the peak value Emax at time Toff.
Effector T cells die a constant per capita rate δE (Figure 1A). With
these assumptions, the dynamics of the virus-specific CD8 T cell
response are given by the following equations:
E(t) =
{
E0eρt, t < Toff,
E0eρToff − δE(t −Toff), t ≥ Toff. (1)
The model for the dynamics of YFV-specific CD8 T cell
response describes accumulation and loss of T cells in circula-
tion. Activation of antigen-specific T cells occurs in secondary
lymphoid organs such as lymph nodes or the spleen. Therefore,
to determine the impact of the cell dynamics in SLOs on accu-
mulation and loss of activated T cells in circulation we use the
FIGURE 1 | Schematic cartoon of the kinetics of virus-specific CD8 T
cell (A) and antibody-secreting cell (B) responses. CD8 T cell response
is broken down into the expansion phase, peak, and contraction phase.
During the expansion phase, CD8 T cells experience massive growth and
reach a peak value at t = Toff. Once this point is reached, CD8 T cell
numbers begin to decline at a rate δE . Antibody-secreting cells (ASCs)
population starts expanding after the initial delay given by Ton. Similarly as
T cells, ASC population grows exponentially at a rate ρ until the peak,
declines exponentially after the peak at a rate δB until reaching memory
phase at time Tmem. Long-term loss of virus-specific ASCs is given by δM
which was set to zero in model fits due to short duration of the
experiments.
Frontiers in Cellular and Infection Microbiology www.frontiersin.org January 2015 | Volume 4 | Article 177 | 2
Le et al. Human immune response to vaccines
following model:
dEL(t)
dt
=
{
(ρL − mLB)EL(t), if t < Toff,
−δEEL(t), otherwise, (2)
dE(t)
dt
=
{
mLBEL(t) − mBTE(t), if t < Toff,
−δEE(t), otherwise, (3)
where EL(t) and E(t) are the density of YFV-specific CD8 T cells
in the SLOs and circulation at time t since infection, respectively,
ρL is the rate of expansion of YFV-specific CD8 T cell population
in the SLOs, mLB is the rate of T cell migration from SLOs into
circulation, mBT is the rate of activated T cell migration from
the circulation to tissues during the expansion phase, and δE is
the rate of apoptosis of activated YFV-specific CD8 T cells after
the peak of the immune response. In the model we assume that
cells in circulation do not divide during the expansion phase
because we expect that T cells spend only a limited time in cir-
culation (Ganusov and Auerbach, 2014). Including expansion of
YFV-specific CD8 T cell response in the blood did not affect the
conclusions from the model. During the contraction phase we let
cells to die both in SLOs and in circulation, and as the infection is
cleared we expect little migration of activated T cells to peripheral
tissues.
It should be noted that in this version of the model we assume
that activated T cells in circulation do not re-enter SLOs. If
the immune response occurs in lymph nodes, the likelihood of
lymphocyte re-entry into the same lymph node is low because
there are hundreds of LNs in humans (Trepel, 1974). However,
if immune response is generated in the spleen, activated T cells
in circulation may be able to re-enter this organ. The model that
includes generation of the immune response in the spleen and re-
entry of activated T cells into the spleen from circulation will be
presented elsewhere.
To predict kinetics of yellow fever virus (YFV) growth and
clearance we assume that the virus population is growing expo-
nentially and is controlled by the CD8 T cell response which
kills virus-infected cells. While we do not know the life-span of
free YFV particles, for several viruses such as HIV and HCV,
free viral particles are removed very rapidly from circulation
(Ramratnam et al., 1999; Guedj et al., 2013), and thus the density
of the free viral particles should be proportional to the density
of infected cells (Perelson, 2002). Therefore, under the assump-
tion of a rapidly cleared free virus, the dynamics of YFV can be
described by the following simple mathematical model:
dV(t)
dt
= V(t)
(
r − [kE(t)]
n
1 + [hE(t)]n
)
, (4)
where V(t) is the density of the virus in the blood (in PFU/ml)
in vaccinated individuals at time t after infection, r is the rate of
virus replication, k is the efficacy at which YFV-specific CD8 T
cells kill YFV-infected cells, 1/h is the percent of the YFV-specific
CD8 T cells at which killing of infected cells is half maximal, n
is the Hill coefficient, and the dynamics of the T cell response is
given by Equation (1).
2.3. MATHEMATICAL MODEL FOR HUMORAL IMMUNE RESPONSE
KINETICS
To describe the dynamics of antibody-secreting cells (ASCs) fol-
lowing vaccinia virus (VV) vaccination of human volunteers we
extend the model for the CD8 T cell response (see Equation 1)
by including an initial delay in the expansion kinetics (Ton) and
the memory phase following contraction of the immune response
after the peak (Figure 1B). It is well known that antibody-
secreting cells produce large amounts of antibodies but it has not
been determined whether ASCs in the circulation are responsible
for the majority of virus-specific antibodies detected in plasma.
To investigate this issue we consider three complementary math-
ematical models. In the first model, ASCs in the blood produce
antibodies at a constant rate and are responsible for the observed
levels of virus-specific antibodies in circulation. The dynamics of
ASCs (B) and antibodies (A) are given by the following equations
(see also Figure 1B):
dB(t)
dt
=
⎧⎪⎪⎪⎨
⎪⎪⎪⎩
0, if t < Ton,
ρB(t), if Ton ≤ t < Toff,
−δBB(t), if Toff ≤ t < Tmem,
−δMB(t), otherwise,
(5)
dA(t)
dt
= θB(t) − δaA(t), (6)
where θ is the per capita rate of production of antibodies by
virus-specific ASCs, and δa is the natural decay rate of antibod-
ies assumed to be δa = 0.0495 day−1 corresponding to a half-life
of 2 weeks (Slifka et al., 1998; Kindt et al., 2007). The impact of the
antibody decay rate δa on our results is outlined in the Discussion
Section.
In the second model we assume that ASC and antibody
dynamics follow the same model (Equations 5–6) with the rate
of antibody production increasing with time since immunization
at a rate α,
θ(t) =
{
θ0, if t < Ton,
θ0 + α(t − Ton), otherwise. (7)
The dynamics of antibodies in circulation is then given by the
equation
dA(t)
dt
= θ(t)B(t) − δaA(t), (8)
where the dynamics of ASCs is given by Equation (5). Increase
in antibody production with time may occur because of transi-
tion of antibody-producing cells from plasmablasts to long-lived
plasma cells. Although it was suggested by several experts in the
field, we were unable to find direct experimental evidence for the
increase in the antibody production rate by ASCs over the course
of infection.
Finally, in the third model we allow ASCs in the circulation
to differentiate into long-lived plasma cells which then migrate
to peripheral tissues such as bone marrow. Such production of
long-lived plasma cells in the bone marrow has been well docu-
mented following LCMV infection of mice (Slifka et al., 1998). In
Frontiers in Cellular and Infection Microbiology www.frontiersin.org January 2015 | Volume 4 | Article 177 | 3
Le et al. Human immune response to vaccines
this model, naive B cells differentiate into antibody-secreting cells
(B) and the number of ASCs increases exponentially. Following
the peak of the response, ASCs die at a rate δB or migrate at a
rate m to the bone marrow where they rapidly differentiate into
long-lived plasma cells (M). In the model, virus-specific antibod-
ies in circulation (A) accumulate due to production by ASCs in
the circulation and by plasma cells in the bone marrow; the rate
of antibody production by these cells is θ . The dynamics of circu-
latory ASCs (B), long-lived plasma cells in the bone marrow (M),
and antibodies in the blood (A) are then given by equations:
dB(t)
dt
=
⎧⎪⎪⎪⎨
⎪⎪⎪⎩
0, if t < Ton,
ρB(t) if Ton ≤ t < Toff,
−(δB + m)B(t), if Toff ≤ t < Tmem,
−δMB(t), otherwise,
(9)
dM(t)
dt
=
{
0, if t < Toff,
mB(t), if Toff ≤ t < Tmem, (10)
dA(t)
dt
= θ(B(t) + M(t)) − δaA(t). (11)
2.4. STATISTICS
The data and model predictions were log-transformed to allow
for normally distributed residuals. Data on the YFV-specific CD8
T cell response were fit using the NLS routine in statistical package
R. We also used non-linear mixed effects (NLME) routine from R
to investigate the importance of variability in model parameters
to reproduce immune response kinetics. For the NLME routine,
the data from all subjects were taken into account. Non-linear
least squares (NLS) routine was used to fit mathematical mod-
els to data from subjects that possessed measurements for at least
five time points. The system of differential equations were solved
using deSolve routine in R. The quality of the model fits to data
was compared using either F-test for nested models or Akaike
Information Criterion, AIC (Bates and Watts, 1988; Burnham
and Anderson, 2002). Confidence intervals for the parameters
were estimated using standard intervals from nls/nlme rou-
tines in R. Fits of the models to the kinetics of antibodies and
ASCs following VV vaccination was done in Mathematica 5.2.
3. RESULTS
3.1. EXPANSION RATE OF CD8 T CELL RESPONSES DETERMINES PEAK
MAGNITUDE
To investigate which parameters determine the magnitude of the
antigen-specific CD8 T cell responses in humans, we analyzed
kinetic data from a recent trial of Yellow Fever vaccine (YF-17D)
in human volunteers (Miller et al., 2008; Akondy et al., 2009). We
fitted a mathematical model (see Equation 1 and Figure 1A) to
the data on kinetics of HLA-A2-restricted CD8 T cells recogniz-
ing NS4B epitope of YF-17D (Akondy et al., 2009) and estimated
parameters of the model (Figure 2). Despite being extremely sim-
ple, the mathematical model describes experimental data well
(Figure 2). Following immunization, YF-17D-specific CD8+ T
cells proliferated rapidly, and the model predicts the rate of expo-
nential increase in the total size of the virus-specific CD8 T cell
response of ρ = 0.37/day (or doubling time of 1.8 days, Table 1).
By assuming that CD8 T cell response is activated at the time
of vaccination, we predict that on average, 1 in 104 of naive CD8
T cells in circulation are specific for the NS4B epitope of YFV
(Table 1). This is on a higher end of directly estimated precur-
sor frequencies of antigen-specific CD8 T cells in humans (Alanio
et al., 2010; Jenkins and Moon, 2012). If T cells are activated
later time points after vaccination, the model would predict even
higher precursor frequency (results not shown). Importantly, we
found that parameters characterizing initial expansion kinetics
of the YFV-specific CD8 T cell response, ρ and E0, were not
significantly correlated (p = 0.12), suggesting that both param-
eters independently contribute to the magnitude of the immune
response.
Our model allows for a more precise estimate of the timing
(Toff) and the value (Emax) of the peak of the YFV-specific CD8 T
cell response (Table 1). The model predicts that on average, the
immune response peaks at 16.5 days post vaccination and reaches
the maximum of 6% of the total CD8 T cells in circulation. Both
values are different from parameters determined for murine CD8
T cell responses specific to another acute viral infection, LCMV,
where immune responses peak 7–8 days post infection and T cells
specific to a single viral epitope can reach 30–50% of the total
CD8 T cell pool (De Boer et al., 2001, 2003). Finally, the model
predicts the loss of activated YFV-specific CD8 T cells at an aver-
age rate δE = 0.02 per day which is equivalent to half-life of 35
days. This is also a much slower decay than that observed for
murine CD8 T cells (De Boer et al., 2003). Finally, by knowing
the initial and final frequency of YFV-specific CD8 T cells, we esti-
mate that the observed expansion of the CD8 T cell response was
achieved in less than 9 divisions. This is surprisingly low since
murine CD8 T cells divide > 10 − 12 times (and possibly more
than 15 times) during acute viral or bacterial infections (Blattman
et al., 2002; Stemberger et al., 2007; Obar et al., 2008; Miller et al.,
2008).
Our analysis allows to investigate which parameters deter-
mine the peak of the immune response and the duration of
elevated numbers of YFV-specific CD8 T cells. Interestingly, we
found that not the initial precursor frequency but the rate of
expansion of CD8 T cell response is determining the peak magni-
tude of the immune response (Figures 3A,B). This is in contrast
to several earlier findings in mice where the peak of T cell
responses was strongly correlated with the precursor frequency
of naive T cells (Moon et al., 2007; Obar et al., 2008; Jenkins
and Moon, 2012); our results are more consistent with another
study suggesting importance of T cell expansion kinetics in deter-
mining immunodominance (La Gruta et al., 2010). To investigate
this issue further, we re-fitted our mathematical model to the
immune response data using non-linear mixed effects models
by allowing only some parameters to vary between individuals.
The best fit of the data was obtained with only the expansion
rate ρ being varied between subjects (Figure S1 and Table S1
in Supplemental Information). Allowing for variability in pre-
cursor frequency between subjects did not improve the quality
of the model fit to data further suggesting that precursor fre-
quency did not play the major role in the determining immune
response dynamics (p = 0.6, likelihood ratio test). Interestingly,
the NLME-based fits of the model to data with only expansion
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FIGURE 2 | Kinetics of the YF-17D-specific CD8 T cell response in
vaccinated volunteers and predictions of the mathematical model.
We fit the mathematical model given in Equation (1) (see Materials and
Methods) to experimental data on the percent of virus-specific CD8 T
cells in blood of volunteers and estimate model parameters. Only
subjects with at least 5 measurements were included in the analysis
because smaller number of data points did not allow estimation of
model parameters and associated errors using non-linear least squares.
Data are shown by circles and model predictions by lines. Individual
panels are data from different subjects with patient labels shown at the
top left corner. Estimated parameters of the model are shown in
Table 1.
rate varied between subjects were significantly better than the fits
in which we estimated individual parameters for every immu-
nized volunteer (AIC = 87.1 vs. 109.0 for NLME vs. NLS fits,
respectively).
We investigated whether any of the model parameters deter-
mine the magnitude of the frequency of YFV-specific memory T
cells. Since our measurements did not establish the time when
memory T cells are formed, we let the number of activated
CD8 T cells found in circulation 100 days post immunization
to represent memory T cells. Previous work established that
vaccination with vaccinia virus leads to formation of a stable
population of memory CD8 T cells by this time (Miller et al.,
2008). Interestingly, no individual parameter for the immune
response, including the rate of the immune response expansion
ρ was predictive of the percent of memory T cells found 100 days
post vaccination (p > 0.05, results not shown). Interestingly, the
estimated peak of the immune response Emax was not strongly
correlated with the memory T cell levels (Figure 3C) since the
significance of the correlation was dependent on selection of all
or only subset of individuals in the analysis (Figure 3C). The
results were similar if we used non-parametric tests for the anal-
ysis (results not shown). Furthermore, by random resampling
our estimates with replacement we found that in nearly 30%
of cases, the correlation between Emax and Emem are not sta-
tistically significant at p = 0.05 level. The absence of strong
correlation between peak immune response and predicted lev-
els of memory T cells are in sharp contrast with studies in mice
where such correlation was established (Murali-Krishna et al.,
1998).
Finally, we asked which parameters determine the time when
the frequency of YFV-specific CD8 T cells declines to a level of
naive T cells if the rate of decline of virus-specific CD8 T cells
after the peak does not change over time. On average, this time
was 378 days. Interestingly, neither the rate of expansion of CD8
T cell response nor the peak immune response was predictive of
the time of the immune response loss (results not shown). Rather,
the rate of loss of activated CD8 T cells, δE, was strongly corre-
lated with the time of the loss of virus-specific T cells (p < 0.001).
Taken together, our analysis provides novel basic information
on the kinetics of CD8 T cell responses to a viral infection in
humans and highlight the importance of the parameters deter-
mining the rate of immune response expansion and contraction
for predicting peak effector response and duration of immune
memory.
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Table 1 | Model parameter estimates.
Patient E0, % ρ, day−1 T off, day δE, day−1 Emax, %
B03 0.0182 [0.00004–0.069] 0.28 [0.13–0.50] 19.2 [10.3–28.1] 0.014 [0.001–0.07] 4.3
B07 0.0070 [0.00001–0.027] 0.47 [0.30–0.67] 16.4 [11.6–21.2] 0.036 [0.010–0.08] 14.9
B11 0.0043 [0.00001–0.017] 0.36 [0.20–0.57] 15.3 [09.1–21.6] 0.015 [0.001–0.07] 1.1
C01 0.0133 [0.00003–0.051] 0.33 [0.18–0.54] 15.6 [08.7–22.4] 0.010 [0.007–0.08] 2.4
E01 0.0259 [0.00005–0.099] 0.27 [0.12–0.48] 18.2 [08.9–27.4] 0.008 [0.011–0.08] 3.4
E06 0.0048 [0.00001–0.018] 0.47 [0.30–0.67] 15.8 [10.9–20.6] 0.017 [10−6–0.07] 7.8
E07 0.0109 [0.00002–0.042] 0.49 [0.32–0.69] 15.7 [11.1–20.3] 0.022 [0.001–0.07] 23.3
E09 0.0045 [0.00047–0.013] 0.45 [0.33–0.58] 14.4 [11.0–17.8] 0.026 [0.007–0.06] 2.8
F04 0.0073 [0.00001–0.028] 0.37 [0.21–0.57] 14.5 [8.50–20.4] 0.014 [0.001–0.07] 1.5
F06 0.0105 [0.00002–0.040] 0.42 [0.26–0.63] 15.8 [10.5–21.0] 0.024 [0.002–0.07] 8.4
F09 0.0053 [0.00001–0.020] 0.32 [0.17–0.53] 19.3 [11.3–27.3] 0.011 [0.005–0.07] 2.7
F13 0.0035 [0.00001–0.013] 0.29 [0.14–0.51] 22.6 [13.3–31.8] 0.038 [0.011–0.08] 2.6
G05 0.0152 [0.00004–0.064] 0.38 [0.16–0.68] 11.9 [06.8–17.1] 0.024 [0.005–0.06] 1.4
H01 0.0149 [0.00003–0.057] 0.37 [0.21–0.58] 16.7 [10.5–22.8] 0.023 [0.001–0.07] 7.3
Mean 0.0104 0.37 16.5 0.02 5.99
Stdev 0.0065 0.07 4.7 0.01 6.26
We list estimates of parameters of the model given in Equation (1) fitted to the experimental data on the kinetics of YF-17D-specific CD8 T cells in vaccinated
volunteers. Listed parameters are E0 is the predicted initial percent of virus-specific CD8 T cells (calculated as the percent of YFV-specific CD8 T cells out of total
CD8 T cell population), ρ is the rate of expansion of virus-specific CD8 T cell response, Toff is the predicted time of the immune response peak, δE is the rate of
decline of the immune response after the peak, and Emax is the predicted peak percent of the YFV-specific CD8 T cells. Note that Emax is not directly estimated
from the data but it is defined as Emax = E0e ρToff (see Equation 1). We also list 95% confidence intervals (in brackets) as provided by the nls routine in R.
FIGURE 3 | The rate of expansion of the YFV-specific CD8 T cell
response and not precursor frequency predicts peak immune
response. For every patient we plot the predicted peak of the immune
response (Emax) vs. estimated precursor frequency E0 (A) or the
expansion rate ρ (B, see Table 1). Also, we plot a correlation between
the frequency of memory CD8 T cells specific to YFV found 100 days
post immunization, Emem = E(100) (see Equation 1), as the function of
the predicted peak of the immune response Emax (C). P-values for
linear regressions are shown on individual panels. In (C) we show
regression for the full data (solid line) and the regression with one
(small dashing line and red circle) or two (large dashing line and blue
circle) outliers removed.
3.2. VIRAL CLEARANCE IS CORRELATED WITH EXPANSION OF
YFV-SPECIFIC CD8 T CELL RESPONSE
YF-17D is a live viral vaccine, and the virus can be easily detected
in the blood of vaccinated individuals (Akondy et al., 2009). In
the vaccinees, the peak viral load in the blood is reached on
average 5 days post immunization, and the virus was cleared
within 2 weeks post immunization (Figure 4). Although both cel-
lular and humoral immunity may contribute to viral control in
immunized individuals, we set to investigate whether expansion
kinetics of the YFV-specific CD8 T cell response is consistent
with the clearance of the YFV in circulation. Clearance of sev-
eral viruses, such as influenza and lymphocytic choriomeningitis
virus (LCMV) is correlated with the rise in virus-specific CD8 T
cells (Lau et al., 1994; Doherty and Christensen, 2000; De Boer
et al., 2001). However, virus-specific CD8 T cell response in mice
expand significantly faster than T cell population specific to YFV
(De Boer and Perelson, 1998; De Boer et al., 2001; Althaus et al.,
2007, Table 1) and therefore we may expect that slowly expand-
ing human YFV-specific T cell responses may not be able to
adequately describe viral clearance.
Therefore, we fitted a simple mathematical model for the
dynamics of virus to the experimentally measured YFV titers in
immunized volunteers (see Equation 4 and Figure 4). In our basic
model we assumed that expanding CD8 T cell response clears
the virus-infected cells at the rate that is proportional to the
density of YFV-infected cells and YFV-specific T cells (so-called
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FIGURE 4 | CD8 T cell expansion kinetics explain clearance of yellow
fever virus. We use parameter estimates for an “average” individual (last
row in Table 1) to predict the kinetics of clearance of YFV in the blood with
a simple mathematical model (Equation 4). Data are shown as points. Two
types of model fits to data are shown: (1) model in which killing of the virus
population follows the law of mass-action (h = 0, n = 1, dashed line), and
(2) model in which killing of the virus population is saturated at high CD8 T
cell densities (h > 0, n = 50). We find that the best fit is provided by the
model in which killing of virus-infected cells saturates at high density of
YFV-specific CD8 T cells even though this improvement in the fit is not
statistically significant due to a low number of data points (F1,4 = 4.94,
p = 0.09). Parameter providing the best fit are V0 = 0.43, r = 2.39 day−1,
k = 24.4 day−1, h = 0, n = 1 (for the mass-action killing model) and
V0 = 0.63, r = 1.73 day−1, k = 13.3 day−1, h = 13.0, n = 50 (for the
saturated killing model). Data point at day 2 was excluded in model fits to
the data as an outlier. Hill coefficient was fixed in model fits of the data. The
virus detection limit in these experiments was 1PFU/ml and is shown by a
thin dashed line.
mass-action, n = 1 and h = 0 in Equation 4). Our recent work
has shown that killing of peptide-pulsed targets by cytotoxic
T lymphocytes in the spleen follows the law of mass action
(Ganusov et al., 2011). Interestingly, slowly expanding YFV-
specific CD8 T cell response was able to predict rapid viral growth
(doubling every 7 h) and viral clearance in less than 2 weeks post
infection (Figure 4, dashed line). However, the description of the
viral load data was not adequate and viral clearance was predicted
to occur 2 days earlier than was actually observed. In the model
this occurred because exponentially growing CD8 T cell popula-
tion was expanding as the virus was being cleared (see Figure 2)
resulting in accelerating virus decay after the peak. Furthermore,
the model also predicted that YFV-specific CD8 T cells started
killing virus infected cells within several days post vaccination
because in this model the estimated replication rate of the virus
(r = 2.4/day) is higher than the actual increase rate of viral titers
during this time period (r0 = 1.7/day was estimated using linear
regression of log-transformed viral titers before the peak viremia).
It is possible, however, that killing in vivo does not follow the
mass-action law, for example, due to competition between killer
T cells for the access to infected targets if the number of effec-
tors greatly exceeds the number of virus-infected cells (Ganusov
and De Boer, 2008; Graw and Regoes, 2009; Gadhamsetty et al.,
2014). The model in which killing of virus-infected cells by the T
cell response saturates at high density of effectors more accurately
explains the rise and clearance of YFV in vaccinated individu-
als (Figure 4, solid line). Interestingly, our analysis suggests that
for the best description of the data, immune response has “all-
or-nothing” effect found at n  1: at low T cell densities, T cells
contribute very little to viral control while at high densities, T cell
killing reaches the maximum. The exact value of the saturation
constant did not play a major role as long as n > 10 since models
with different values of n (n ≥ 10) led to fits of a similar quality
(results not shown).
Importantly, although the fit of the model with saturated
killing leads to a dramatic reduction in the residual sum of squares
(from 0.45 to 0.20), the improvement in the fit quality was not
statistically significant (F1,4 = 4.94, p = 0.09) most likely due to
a limited number of data points. The results were similar if we
extend our analysis by using weighted least squares with mea-
sured error in viral titers for different time points (results not
shown). Extending this analysis to virus and YFV-specific CD8
T cell response kinetics in individual subjects will likely provide
additional insights into whether CD8 T cells are responsible for
viral clearance in YFV-infected individuals or some other effec-
tor mechanisms, e.g., antibody response, must be also involved to
explain the data.
In our analysis we assumed that the rate of expansion of the
YFV-specific CD8 T cell response is given by the average esti-
mate ρ = 0.37 day−1 (Table 1). However, our estimates suggest
that the expansion rate could vary substantially between different
individuals from 0.12 to 0.69 day−1 (including confidence inter-
vals in Table 1). Interestingly, reducing the rate of expansion ρ
from 0.37 day−1 to lower values did not significantly impact the
the quality of the fit of the model with mass-action killing of the
data for most values of ρ (results not shown). However, at very
low expansion rates, e.g., when ρ = 0.1day−1, the model with
mass-action killing was unable to accurately describe the data
as judged by significantly increased AIC score (AIC increased by
8.4). Furthermore, increasing the rate of expansion to higher that
0.37 day−1 values also revealed poor description of the data by the
model with mass-action killing (e.g., at ρ = 0.5 day−1 AIC was
increased by 12.4). Interestingly, the model with saturated killing
(n  1) could still explain the viral clearance data with excel-
lent quality even at lower or higher than 0.37 day−1 expansion
rates, so that the difference in the fits of the models with mass-
action killing vs. saturated killing became statistically significant
at ρ = 0.5 day−1 (F1,4 = 22.4, p = 0.009). This result suggests
that in our models the kinetics of expansion of YFV-specific CD8
T cell response has a strong impact on determining viral clear-
ance kinetics, and that future studies should attempt to determine
mechanisms leading to accumulation and loss of antigens-specific
CD8 T cells in circulation and possible in tissues of humans.
3.3. KINETICS OF VV-SPECIFIC ANTIBODY-SECRETING CELLS AND
ANTIBODIES
While humoral immune responses to haptens and viruses have
been studied for decades, as far as we know there has been no
studies that directly linked dynamics of antigen-specific antibody-
secreting cells (ASCs) and antigen-specific antibodies in humans
in one quantitative framework. Quantification of the antibody
production by individual ASCs has been undertaken previously
using a technique of isolating individual plasma cells (Jerne and
Nordin, 1963; Jerne et al., 1974); yet, the rates of division of ASCs
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and the rate of antibody production by ASCs in vivo in humans
remain to be determined. To provide initial answers to these ques-
tions we analyzed experimental data on the dynamics of ASCs and
antibodies specific to vaccinia virus (VV) in VV-infected individ-
uals (Miller et al., 2008, Figure 5). A low level of virus-binding
antibodies was detected in these individuals, and VV-specific anti-
body titer increased 2-3 orders of magnitude within a week after
1 week delay following vaccination. The frequency of ASCs in
circulation also increased following vaccination (Figure 5). To
investigate how ASC and antibody dynamics are linked we devel-
oped a mathematical model (see Equations 5–6 in Materials and
Methods). The model was fitted to experimental data and the best
fits are shown in Figure 5 as lines.
In the basic model we assume that after an initial delay, ASCs
start proliferating and produce antibodies at a constant rate.
Surprisingly, this simple model was able to accurately capture
the dynamics of both antibody-producing cells and VV-specific
antibodies over 3 months after vaccination (Figure 5). The model
predicted that on average immune response starts expanding 10
days post immunization at the average rate of 1.2 per day (dou-
bling time of 14 h) which appears to be a substantially faster
expansion than that of YFV-specific CD8 T cells (Table 1) or VV-
specific CD8 T cells (see Discussion). The peak of the immune
response occurs at 14 days post immunization which is slightly
earlier than that of YFV-specific CD8 T cells. We found that the
dynamics of VV-specific antibodies can be explained well if ASCs
in circulation produce antibodies at a rate p = 185 relative units
(RU) per 1% of ASCs in circulation per day. In other words,
185 RU of VV-specific antibodies are produced by 1% of ASCs
in circulation per day. To convert these estimates to the rate of
antibody production by individual cells we will need to know the
total number of antibody-producing cells and total amount of
antibodies in circulation; these values were not available from the
original publications (Miller et al., 2008; Akondy et al., 2009).
Although the mathematical model describes the data reason-
ably well, some fits are not completely satisfactory; for example in
Figures 5B–D, the model underestimates the antibody titers 84
days post immunization. Furthermore, some estimated param-
eters appear somewhat unrealistic, e.g., rapid expansion rate ρ
in the donor 141 (Table 2). Therefore, we tested two additional
mathematical models that relax some assumptions regarding ASC
dynamics (see Materials and Methods).
In the first alternative model (Equation 5, 8), we allow ASCs
to increase the rate of antibody production during an immune
response. It is possible that late ASCs make more antibodies on a
per cell basis than early ASCs, although we did not find a direct
experimental evidence for this hypothesis. Allowing for a linear
increase in antibody production rate by ASCs over time allowed
for more reasonable description of accumulation and loss of VV-
specific antibodies and for smaller estimates of the expansion rate
of the ASC population (results not shown). However, because of
the limited number of data points and increased number ofmodel
parameters, this improvement in the quality of the model fit to
data was not statistically significant (p > 0.2 for all donors, F-test
for nestedmodels). In the second alternative model (Equations 9–
11) we allowed ASCs in the circulation to migrate to tissues (e.g.,
bone marrow) and produce antibodies from that distant site. It is
well known that following an immune response the majority of
virus-specific ASCs in mice are found in the bone marrow (Slifka
et al., 1998), and in humans the bone marrow harbors a large
population of plasma cells (Turesson, 1976). This extendedmodel
also allowed for a better description of the dynamics of anti-
body titers and predicted that about 10–20% of circulating ASCs
migrate to the tissues during the contraction phase of the immune
FIGURE 5 | Kinetics of VV-specific antibodies are predicted well by
the accumulation and loss of antibody-secreting cells in the
blood. We fit the basic mathematical model (Equations 5–6, see
Materials and Methods for more detail) to the experimental data
using non-linear least squares. Data are shown as markers (points
are for antibody-secreting cells and triangles are for antibodies), and
lines are the predictions of the mathematical model. The data and
the fits are shown for individual donors in panels A–F, and donor
IDs are indicated on individual panels. Best fit parameters are shown
in Table 2.
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Table 2 | Parameter estimates determining the kinetics of VV-specific antibody-secreting cells and antibodies.
Donor B0, % Ton, day ρ, day−1 Toff, day δB , day−1 Tmem, day A0, RU θ , day−1
70 0.037 11.6 1.17 14.53 0.2 29.5 17.5 108.6
91 0.015 6.6 0.48 16.39 0.32 28.0 2.5 288.2
97 0.022 9.5 1.02 14.79 0.15 28.0 6.7 261.3
116 0.029 11.3 1.77 14.0 0.11 36.0 4.0 98.8
141 0.062 12.7 3.13 14.0 0.36 24.9 3.5 311.0
65 0.537 7.7 1.20 11.84 1.73 14.8 5.0 7.0
Median 0.033 10.4 1.19 14.3 0.26 28.0 4.5 185.0
The best fits of the model to experimental data are shown in Figure 5. Here B0 is the pre-immunization level of ASCs, Ton is the time of the start of proliferation
of VV-specific ASCs, ρ is the rate of expansion of the VV-specific ASC population, Toff is the time of the peak of ASC response, δP is the rate of loss of ASCs from
circulation, Tmem is the time when ASC density stops declining, A0 is the antibody titer prior to vaccination, and θ is the rate of antibody production by VV-specific
ASCs. We assume that VV-specific IgG antibodies have a natural half-life time of 2 weeks which translates into antibody removal rate of δa = 0.0495 day−1 (Slifka
et al., 1998). This value was fixed in fitting of the model to experimental data.
response (results not shown). Yet, the model fits of the data were
not statistically improved (p > 0.15, F-test for nested models).
Future studies by providing more frequent measurements of the
ASCs and antibodies are likely to improve our quantitative under-
standing of humoral immune responses to vaccination and may
allow to reject the simple model (that assumes that most of anti-
bodies in circulation at 90 days post immunization come from
ASCs in circulation).
4. DISCUSSION
Basic features of the immune responses to viruses, causing acute
infections, appear to be similar in mice and humans. Antigen-
specific lymphocytes are activated shortly after the infection;
activated lymphocytes proliferate for 7–20 days. After reaching
the peak of the immune response many activated cells die and
a smaller population of resting lymphocytes survive. For CD8 T
cell responses, approximately 5–10% of effector T cells present at
the peak of the immune response survive into memory (Kaech
and Cui, 2012); memory T cells provide protection following re-
exposure to the same infection (Mbow et al., 1994; Co et al.,
2002; Miller et al., 2008; Santos et al., 2008). In contrast, during
humoral immune response effector lymphocytes (ASCs) survive
into the memory and become long-lived plasma cells (Slifka et al.,
1998).
While basic features of the virus-specific immune responses
are well understood, parameters determining the kinetics of
immune responses in humans are not known. In particular, only
recently the frequency of human naive T cells specific to sev-
eral different antigens has been identified (Jenkins and Moon,
2012). Our analysis extends previous work by providing quantita-
tive estimates of the parameters defining kinetics of CD8 T cells,
ASCs, and antibodies specific to live viral infections of humans.
We found that the population of CD8 T cells specific to
NS4B epitope of YFV expands relatively slowly with the aver-
age doubling time of 2 days reaching the peak of the immune
response 2.5 weeks post immunization (Figure 2). Analysis of
the additional data on the kinetics of VV-specific CD8 T cell
response in one patient revealed a similar expansion kinetics
at a rate ρ = 0.44 day−1 (doubling time of 1.6 days) with the
observed peak 2 weeks post infection (results not shown and
Miller et al., 2008). This is in sharp contrast with the kinetics
of the virus-specific CD8 T cell responses in mice where T cell
response expands at a much faster rate (ρ = 2 − 3 day−1, dou-
bling time every 6–8 h) and peaking 7–8 days post infection
(De Boer and Perelson, 1998; De Boer et al., 2001). The rate of loss
of activated T cells after the peak is also slower in humans than in
mice (0.02–0.04 per day vs. 0.20 per day in humans and mice,
respectively). Interestingly, the estimated rates for human volun-
teers are relatively close to the rates of expansion and contraction
of the CD8 T cell response against simian immunodeficiency
virus in macaques (Davenport et al., 2004). In accord with some
but not all studies we found that the peak frequency of the YFV-
specific CD8 T cells is mainly determined by the rate of expansion
of T cell response (La Gruta et al., 2010). Finally, we found that the
predicted peak of the immune response in humans did not cor-
relate significantly with the frequency of memory T cell formed
which is also in contrast with observations in mice (Doherty and
Christensen, 2000).
It should be emphasized, however, that kinetic parameters for
the T cell response in mice have been obtaining using data from
secondary lymphoid organs such as spleen, while our analysis is
for the T cells found in circulation. We have developed a sim-
ple model in which proliferation of antigen-specific CD8 T cells
occurs in secondary lymphoid organs (SLOs) at a rate ρL; acti-
vated T cells leave SLOs into the circulation at a rate mLB, and
cells in the blood migrate to peripheral tissues at a rate mBT (see
Equations 2–3 in Materials and Methods). Direct solution of this
mathematical model suggests that after an initial delay the density
of virus-specific CD8 T cells in the blood increases exponentially
at a rate ρ = ρL − mLB (result not shown). Therefore, the rate
of increase in the density of YFV-specific T cells in the circula-
tion is proportional to that of T cells in SLOs; however, the small
value for the expansion rate ρ for the YFV- and VV-specific CD8
T cells may not represent slow division of these cells but rather
a balance between cell division in SLOs and the cell exit into cir-
culation. The kinetics of lymphocyte exit from SLOs during an
immune response in humans are not known, and in fact, as far
as we know, the rates of exit of activated T cells from lymph
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nodes or the spleen have not been quantified even in mice. We
have recently estimated that thoracic duct lymphocytes, which
consist mostly of resting T cells, spend on average 2.5 h in the
spleen and 10 h in the lymph nodes or Peyer’s patches (Ganusov
and Auerbach, 2014). Inflammation did not impact the residence
time of these cells in lymph nodes. Our unpublished work also
suggests that blood-derived lymphocytes spend 20–30 h in ovine
lymph nodes in the absence of inflammation (McDaniel and
Ganusov, ms. in preparation). If activated T cells spend about 1
day in human lymph nodes (mLB ≈ 1 day−1), then our simple
mathematical model suggests that following a live viral infection,
virus-specific CD8 T cell population expands at a substantial rate,
ρL = ρ + mLB = 1.4 day−1. Thus, our analysis provides minimal
estimates of the expansion rates of virus-specific CD8 T cell popu-
lations in humans. Additional analysis also demonstrates that the
estimated precursor frequency E0 is proportional to the frequency
of naive T cells in the SLOs, with the proportionality coefficient
being dependent on the rates of lymphocytes migration in and
out of circulation (results not shown).
If expansion kinetics of CD8 T cell responses in humans is
indeed much slower than that in mice, it remains unclear why
this is the case. Many processes occur more rapidly in mice than
in humans (e.g., heartbeat), so differences could arise due to
differences in the metabolic rates (Demetrius, 2005). Precise rea-
sons for differences in immunological response kinetics, however,
remain to be investigated. Analysis of the kinetics of CD8 T cell
response in major SLOs and the blood to a local infection of mice
could provide valuable information on the processes impacting
accumulation and loss of antigen-specific CD8 T cells in the
circulation.
Despite slow expansion of the YFV-specific CD8 T cell
response, the rise in the frequency of antigen-specific T cells was
predictive of the clearance of YFV in circulation. However, since
we analyzed average viral load data from multiple individuals it
remains to be determined if expansion of virus-specific T cell
population in individual subjects is predictive of viral clearance
in the same subjects. It is important to note that in our analysis
of the viral load data we ignored a decline in the amount of the
virus found at day 2 post infection. The initial rise and decline of
the virus could be a classical example of primary viremia when
the virus spreads from the initial site of infection systemically.
Primary and secondary viremia are well documented features of
cytomegalovirus spread (Gerna, 2012). Because we did not have
viral load data for individual subjects and because our model
was already sufficiently complex, we did not include additional
details for the viral spread within the host generating primary and
secondary viremia if such phenomenon truly exists for YFV.
The correlation between expansion of YFV-specific CD8 T cell
response and viral clearance in vaccinated individuals does not
imply that T cells necessarily contribute to viral control. In fact,
recent work suggests that T cell responses are not responsible for
clearance of the YFV-based vaccine against dengue fever (Slifka,
2014). ChimeriVax is a vaccine in which YF-17D is used as a
vector and in which YFV envelope gene has been replaced with
dengue virus envelope (Slifka, 2014). The dynamics of this live
dengue vaccine virus was similar in naive individuals or in hosts
with pre-existent immunity to YFV (Guirakhoo et al., 2006) sug-
gesting limited role of T cell responses to internal YFV proteins in
control of virus replication (Slifka, 2014). Yet, viremia of the vac-
cine strain in immunized individuals was low and of a very short
duration (1–2 days) which is in contrast to viremia observed in
individuals exposed to YF-17D vaccine (Figure 4). In one well
documented example vaccine-induced T cells are able to con-
trol and in many cases clear SIV infection but clearance often
takes several weeks (Hansen et al., 2013). This result suggests that
impact of virus-specific T cell responses on viral replication could
be more pronounced for infections of longer duration which is
consistent with the idea that vaccine-induced CD8 T cells may
not be able to prevent infections (Slifka and Amanna, 2014).
It is interesting to note that in LCMV-infected mice, the timing
of viral clearance is well correlated with the time when virus-
specific CD8 T cell responses reach their peak suggesting that
constant exposure to the antigen may be needed to sustain expan-
sion of the T cell response (De Boer et al., 2001; Shaulov and
Murali-Krishna, 2008). However, in YFV-infected individuals the
virus is cleared from circulation several days before T cells are
predicted to stop dividing. This may either suggest that viral anti-
gens are still persistent in tissues to allow expansion of the T cell
populations or that CD8 T cell responses are “programmed” in
humans by the early exposure to the infection (Kaech and Ahmed,
2001). Further studies will be needed to discriminate between
these alternative hypotheses.
Our analysis provides basic estimates for the rate of expan-
sion of antibody-producing cell responses following exposure to
VV and the rate of antibody production by these cells. The basic
model in which virus-specific antibodies found in circulation are
due to production by ASCs in circulation can readily explain the
available experimental data. More realistic mathematical models
that include change in the rate of antibody production by ASCs
with time or migration of ASCs to the bone marrow, did not
improve the quality of the model fit to data. We hypothesize that
this occurred because only few measurements over the course
of 3 months were available for the analysis. Also, it remains to
be determined if our estimated rate of antibody production by
ASCs are biologically realistic and consistent with what has been
measured in vivo or vitro in several previous studies (Nossal and
Makela, 1962; Salmon and Smith, 1970; Hiramoto et al., 1972b,a;
Conrad and Ingraham, 1974; Hibi and Dosch, 1986). It should
be noted, however, that previous studies vary dramatically on
the estimates of the rate of production of immunoglobulins by
antibody-secreting cells ranging from 300-500 molecules per sec-
ond (Hiramoto et al., 1972a) to 12,000 and 30,000 molecules per
second (Conrad and Ingraham, 1974; Hibi and Dosch, 1986).
Our re-analysis of data from the most recent study suggests that
plasma cells from trouts make 37 − 150 × 103 IgG molecules per
second (Bromage et al., 2009). The reasons for such large discrep-
ancy in estimates are not known and could arise from different
methods employed to estimate the rate of antibody production.
To provide accurate estimates of the rate of antibody production
by antibody-secreting cells future experimental studies should
attempt to measure the total number of antibody-producing cells
in circulations and in tissues (e.g., bone marrow) and to convert
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the titers of virus-specific antibodies to the actual concentration
of the antibody molecules in circulation.
Our prediction on the kinetics of antibody production by
ASCs is based on the assumption that VV-specific antibodies have
a half-life of 2 weeks. We could not find a study that directly mea-
sured the half-life of VV-specific antibodies, and studies in mice,
monkeys, and humans suggested a wide ranges of half-lives of IgG
molecules ranging from 1 to 5 weeks (Vieira and Rajewsky, 1986,
1988; Slifka et al., 1998; Alyanakian et al., 2003; Salfeld, 2007; Pegu
et al., 2014).
Allowing for a longer half-life of VV-specific antibodies
(smaller value for δa) allowed for a better description of the
long-term dynamics of antibodies in the basic model (results not
shown). This suggests that if VV-specific antibodies have a rela-
tively high half-life, all antibodies found in circulation within 90
days post vaccination are likely to come from ASCs in circulation
making antibodies at a constant rate, and evidence for alternative
models is very weak. The antibody half-life also influenced the
estimate of the antibody production rate by ASCs suggesting that
the rate of loss of virus-specific antibodies is important in calcu-
lating how many antibody molecules one ASC makes per unit of
time in vivo.
Our mathematical modeling-assisted analysis illustrates how
simple kinetic data may provide important insights into dynam-
ics of T cell responses to viruses, the mechanisms of viral control
by T cells, and into how virus-specific antibodies are produced
following vaccination. Our work also highlights problems with
existing data which do not allow to discriminate between alter-
native models. Future experimental studies involving vaccination
of human volunteers may benefit from more frequent measure-
ments of the immune responses and from detailed mathematical
analyses; such joint ventures betweenmodels and data are likely to
generate novel insights into mechanisms leading to more efficient
vaccines.
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